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The evidence for the role ofenvironmental
factors in human cancer is strong in terms
ofgeographic differences in cancer patterns
and the changes in these patterns in
migrants (1). Yet, with some exceptions,
identified carcinogens (even by conservative
risk assessments) appear to be responsible
for only a small fraction of current cancer
deaths (2). The role of tumor promoters
would seem to be important because there
is exposure to large numbers of environ-
mental carcinogens at low dose levels (3)
that, at a minimum, might be expected to
initiate the cancer process. However, the
tumor promoters identified in rodent stud-
ies are commonly regarded as being too
species and strain specific to be of impor-
tance to humans (4).
There is a class of chemicals to which
humans are exposed, namely, the contact
sensitizers, that might be ofinterest because
of their possible role as tumor promoters.
The large number ofsuch agents is suggest-
ed by the fact that conventional dermato-
logical kits for diagnostic patch testing
encompass over 350 chemicals (5). Of
these, 19 are on the Congressionally man-
dated NIH list ofcarcinogens (6)
Contact sensitizers are chemically relat-
ed to genotoxic carcinogens; both classes of
compounds are electrophiles and cause the
adduction ofmacromolecules (7). The con-
tact sensitizers are compounds that cause
nucleophilic aromatic substitution reac-
tions, and their macromolecular adduction
is limited to protein.
Although there is little direct evidence
about the carcinogenic potential ofcontact
sensitizers, suggestive evidence of an over-
lap with carcinogens comes from struc-
ture-activity alerts for contact sensitizers
(8) and carcinogens (9). Of the 41 struc-
tural alerts for contact sensitizers, one-third
are common to those for carcinogens
(D.W. Bristol, personal communication).
In the late 1940s, the concept first
emerged that carcinogenesis is a multistage
process that can be divided into an initia-
tion stage, which is prompt and irreversible
(like the induction of mutations), and a
promotion stage in which there is clonal
expansion of neoplastically transformed
cells into tumors (10). The possible con-
nection between contact sensitizers as pro-
moters and classical tumor promoters is
that they both cause inflammatory reac-
tions at the site of contact, and inflamma-
tion is the hallmark of tumor promotion
(11,12). The association ofchronic inflam-
mation with cancer has been recognized for
over a century (13-16). How inflamma-
tion might cause cancer is unclear.
Inflammatory cells produce oxygen free
radicals (17), which results in oxidized
DNA bases (18) and DNA damage in the
form ofsingle strand breaks, increased sister
chromatid exchanges, and chromosome
abnormalities (11). Activated human leuko-
cytes neoplastically transform 1OT1/2 cells
in culture, which suggests that inflammatory
cells may be carcinogenic; the same effect in
this in vitro system can be produced by a
super oxide generating system (xanthine oxi-
dase andhypoxanthine) (19).
There are at least two basic causes of
inflammation in the skin: the immune-spe-
cific cell-mediated Type IV (delayed-type
hypersensitivity) immune process and irri-
tant-based inflammation produced by a
wide range ofchemical and physical factors.
Cell-mediated immunity is a complex two-
step process. The first or sensitization step
involves the initial skin application of the
contact sensitizer, with the formation of
haptenes from adducted skin proteins, and
activation ofT lymphocytes throughout the
body. The second or elicitation step
involves localization of the activated lym-
phocytes at the site ofthe second skin appli-
cation and the induction ofan inflammato-
ry reaction (20).
Inflammation in the skin from chemical
or physical irritation is due to the release of
cytokines by the damaged keratinocytes in
the epidermis, which causes mobilization of
inflammatory cells and edema (21). There
is no distinction between immunogenic and
irritant inflammation in terms of the types
of inflammatory cells. In principle, contact
sensitizers could produce inflammation by
both immune and irritative (cytotoxic)
mechanisms.
The first link between carcinogens and
contact sensitization was reported in a study
of three polycyclic aromatic hydrocarbon
carcinogens (22). More recently, an evalua-
tion was made ofthe relationship of muta-
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genicity, carcinogenesis, and skin sensitiza-
tion (7). The results on 20 agents, includ-
ing human and rodent carcinogens, clearly
supported the high likelihood that muta-
gens and genotoxic carcinogens are skin
contact sensitizers.
Recent studies on the cytokinetic
responses ofthe mouse skin to chronic top-
ical benzo(a)pyrene (BaP) exposure indi-
cated that there was an inverse relationship
between the dosage level and the degree of
latency in the appearance ofdermal inflam-
mation and epidermal proliferation (23);
such an inverse relationship also applies to
tumor induction and suggests the possibili-
ty that an immune response to BaP might
play a role in the promoting component of
tumorigenesis. A delay in the appearance of
inflammation was also seen with the car-
cinogen dibenz(a,l)pyrene, which was also
interpreted as an immune response (E.
Cavalieri, personal communication).
The hypothesis that contact sensitizers
might be tumor promoters because they
produce an immunogenic inflammatory
reaction implies that individuals who are
allergic hyperreactors to contact-sensitizing
chemicals might be at a relatively high risk
of cancer and the kinetics of promotion
from the promoting component ofcomplete
carcinogens or from contact sensitization
might be based on the kinetics of immune
processes in response to low-level exposure.
The above hypothesis could be tested by
determining whether corticosteroids depress
the inflammation and tumorigenic action of
contact sensitizers. Corticosteroids are com-
monly used for the treatment of immuno-
logical diseases including allergic contact
dermatitis, which is a manifestation of T
cell-mediated Type IV (delayed-type hyper-
sensitivity) immunity. The mechanisms of
action are incompletely understood but
inhibition ofphospholipase A2, an enzyme
that releases arachidonic acid from mem-
brane phospholipids, is considered to be
critical; arachidonic acid is converted to
inflammatory mediators, prostaglandins,
and leukotrienes. Corticosteroids also
inhibit the accumulation of inflammatory
cells, production of interleukins 1 and 2,
and biosynthesis of cyclooxygenase (24);
they are growth inhibitory and can produce
atrophy ofthe skin. Corticosteroids inhibit
tumor promotion by the phorbol ester 12-
O-tetradecanoylphorbol-13-acetate (TPA)
(25), and the degree ofinhibition correlates
with their anti-inflammatory potency ofthe
phorbol esters (26). The tumorigenicity of
the complete carcinogens 7-bromomethyl
benz(a)anthracene (27) and methylcholan-
threne (28) are suppressed in part by the
corticosteroid fluocinolone acetonide (FA).
However, the reverse has also been report-
ed, namely, that FA can enhance tumor
promotion byP-propriolactone (29).
To test the hypothesis that the promoting
action ofcontact sensitizers could be due to
the induction ofan immunogenic inflamma-
toryreaction, weexaminedtheeffectofFAon
the tumorigenic and inflammatory action of
dinitrofluorobenzene (DNFB), a well studied
contact sensitizer and tumor promoter.
DNFB attacks the terminal amino groups on
proteins and has been used to sequence their
amino acid structure (30). It has been shown
to beatumorpromoterforthe skinwhen ini-
tiated with 1,2-dimethyl-3,4-benzanthracene
(DMBA) in four strains of mice: Swiss,
C57BL/6, Balb/C (31), and Sencar (32).
DNFB is not a tumor initiator in the mouse
skin (31), indicating that it is not genotoxic.
DNFB belongs to the protein kinase C-inde-
pendent dass oftumor promoters (32). It is
nonmutagenic in the V79 cell culture system
although it is mutagenic in Escherichia coli
(33). DNFB is not clastogenic nor does it
produce sister chromatid exchanges, but it
does inhibit metabolic cooperation (33); thus,
DNFB has many ofthe usual characteristics
of a tumor promoter. Although it is not as
potent as TPA on a molar basis, DNFB is
similar in thatitislesseffective in somemouse
strains than in others, e.g., C57BL/6 com-
pared to the Swiss (31).
The skin tumor promotion model
selected for this studywas the TG.AC trans-
genic mouse. This transgenic model incor-
porates a fetal 1-globin promoter fused to a
v-Ha-ras structural gene with mutations at
codons 12 and 59, which is linked to a simi-
an virus 40 polyadinylation splice sequence
(34). The skin ofthis mouse behaves as ifit
were genetically preinitiated and has the
great advantage of a very rapid and profuse
papilloma response to even a few applica-
tions of a promoting agent (35). We used
TPAas apositive control for DNFB.
In the study reported here, we found
that FA, when applied together with
DNFB, produced only a small reduction in
the inflammatory response and no reduction
in the tumorigenic response; this is in con-
trast to the effect ofFA on TPA. With daily
doses ofFA, the damaging effect of DNFB
on the skin was worsened and the inflam-
mation and tumor response increased. These
results suggest that tumorigenesis, produced
by relatively high-level, short-term dosing
with DNFB, is due to cytotoxicity and not
to immunogenic inflammation.
Materials and Methods
Female homozygous TG.AC mice were
obtained from Taconic Farms (German-
town, PA) at 4-5 weeks ofage. They were
quarantined for 1 week and housed four to
a cage in rooms maintained at 70°F with a
12-hr light/dark cycle. The mice were fed
Purina Pico Chow 5058 and water adlibi-
tum. The mice were shaved with electric
clippers on the day offirst skin application
and as needed. Mice were enrolled in dif-
ferent experiments at ages ranging from 16
to 32 weeks.
Reagant grades DNFB, FA, and TPA
were obtained from the Sigma Chemical
Company, St. Louis, MO. DNFB was
applied in 4:1 acetone/olive oil, and FAand
TPA were applied in acetone. Applications
ofDNFB and TPAto the dorsal skin ofthe
back were made in I00-il volumes. FA was
applied about 30 min before DNFB or
TPA, when given close together. FA was
administered in a volume of 150 pil to
insure that DNFB andTPAwere applied to
FA-treated skin.
Tumor induction by DNFB or TPA
was routinely done by applying two doses
perweek for 2 consecutive weeks for a total
offour applications. Animals were initially
observed several times a week for skin
changes on the back and then for the
appearance of tumors at 1-week intervals.
Tumor formation was expressed as the
prevalence of tumors per mouse because
mortality during the tumor formation peri-
od was negligible. The size of treatment
groups ranged from 4 to 16 mice each,
depending on the experiment.
Contact sensitization was induced by
applying four doses ofDNFB orTPA to the
dorsal skin of the back, as described for
tumor induction. The sensitization response
was elicited after a 7-day interval by the
application of DNFB or TPA at nonirritat-
ing concentrations to either the dorsal sur-
face or both surfaces ofthe ear in 20-jl vol-
umes under fluothane:oxygen anesthesia. Ear
thickness was initially measured 24 and 48
hr later using the same anesthetic. Only the
24-hr measurements were made when we
ascertained, as did others (36), that the max-
imum response was obtained at 24 hr. The
ear thickness measurements were made with
a Dyer micrometer (Dyer Corporation,
Lancaster, PA). This device opposes two steel
disks of 5-mm diameter at a constant pres-
sure and measures the amount ofseparation
in hundredths of a millimeter. Care was
taken to apply the disc consistently about 3
mm from the tip ofthe ear inorderto obtain
reproducible measurements because the ears
in mice are tapered; care was also taken to
ensure that the application ofthe sensitizing
agent covered the measured area. The results
were expressed as the difference between the
ear thickness before and after the application
oftheeliciting dose to the ear.
Histological sections ofthe treated skin
were obtained for evaluation ofthe inflam-
matory reaction in the dermis several days
Environmental Health Perspectives * Volume 104, Number 10, October 1996 1063Articles - Albert et al.
after the last dose ofthe agent under study.
Two adjacent transverse strips ofskin, sev-
eral millimeters wide, were taken from the
treatment area of each mouse and fixed in
10% formalin. Two paraffin-embedded sec-
tions, perpendicular to the surface of the
skin, were cut from each strip. The sections
were 6 pxm thick and were stained with
Feulgen reagent to highlight the cell nuclei
and counterstained with Fast Green. The
slides were examined in an image analysis
unit using the NIH Image 1.54 program
(National Institutes of Health, Bethesda,
MD). This permitted measurements ofthe
inflammatory reaction in terms ofthe num-
ber ofcell nuclei in the dermis between the
hair follicles per unit area. An oil-immer-
sion objective was used to measure cell den-
sity, and the resulting image on the moni-
toring screen was 80 x 60 pm with an
enlargement of 340x. The cell density was
equal to the number ofcell nuclei per 4400
Pm2. Dermal thickness was measured as the
distance between the bottom ofthe epider-
mis and the top of the hypodermis. A 10-
power objective was used to measure der-
mal thicknesses with a magnification of
34x. Five areas from each slide were mea-
sured for cell counts and dermal thickness.
Two slides were examined from each ofthe
two skin strips per animal and two animals
were used for each treatment group. The
product ofthe cell density and the thickness
of the dermis was used as an index of
inflammation because it roughly reflected
the total number of cells in the dermis. In
each treatment group, the means and stan-
dard deviations of the inflammation index
were determined on the basis of the aver-
aged values for each of the four skin strips
from the two mice. The standard error of
the mean was taken to be the same as the
standard deviation. Statistical comparisons
of the effects of FA on the inflammatory
response to DNFB, i.e., treatment groups
receiving DNFB alone or the same regimen
of DNFB together with FA, were again
based on the mean inflammation index
from the four skin strips from the two mice
in each treatment group; the standard devi-
ation of the difference between treatment
groups was the square root ofhalfthe sum
ofthe squares ofthe deviations within treat-
ment groups; i.e., deviations of the indices
from the two mice in each treatment group
from the group mean. The standard error
was equal to the standard deviation. The t
values were the differences between the
means of the treatment groups divided by
the relevant standard deviation; the two-
tailedp-values were based on the values of t
for 2 degrees of freedom. Other statistical
calculations were done with EXCEL 5.0
(Microsoft Corporation, Redmond, WA).
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Figure 1. Tumor prevalence (tumors per mouse) atthe indicated times afterthe first exposureto dinitroflu-
orobenzene (DNFB) shown according to dose.
Results
The gross and histological appearances of
the DNFB-induced skin tumors were typi-
cal ofkeratinizing papillomas although one
subepidermal keratinizing lesion was found
and diagnosed to be a keratoacanthoma. At
high doses of DNFB (i.e., 0.25% or 0.5%
exposure) where there was extensive skin
damage, the tumors forming at the margins
of healing ulcers were considerably larger
than those on the same mice away from the
ulcerated areas or in other mice that were
given lower nonulcerogenic doses ofDNFB.
Figure 1 shows the temporal pattern of
tumor formation in terms of tumor preva-
lence in relation to the number ofweeks
after the first exposure. In this experiment
the number of starting mice per group
ranged from 9 to 15 mice. The acetone con-
trols and DNFB doses of 0.125% and
0.25% were given in four applications. Skin
damage at 0.5% DNFB limited the applica-
tions to two. Tumor formation began at
about 4weeks and reached aplateau at about
8 weeks. At 8 weeks, the standard error, as a
percentage of the tumor prevalence, ranged
from 36% at 0.125%, to 9% and 5% at
0.25% and 0.5% DNFB, respectively.
Figure 2 illustrates the rapid rate of
tumor formation in terms ofthe total num-
ber of new tumors forming each week in
each treated group for several doses of
DNFB. The tumor formation rate peaked
at about 5.5 weeks, and no new tumors
were observed after about 8 weeks. The loss
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Figure 2. The rate of tumor formation (the number
of newtumors forming perweek) according to the
dose of dinitrofluorobenzene (DNFB) and weeks
after initial exposure.
of mice and the regression of tumors was
not significant in this briefperiod oftumor
formation so a correction for mortality was
not needed. Over a period of months, the
tumors shrivelled, darkened, and fell off
resulting in a substantial reduction in
tumorprevalence.
The dose-response curve for tumor
prevalence at 8 weeks after the first expo-
sure for the four-dose regimen is shown in
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Figure 3. The dose-response curve for tumor
yield at8weeks after initial exposure to dinitroflu-
orobenzene (DNFB). A quadratic curve is fitted to
the data.
Figure 3. The dose-response curve was
based on five experiments. There were
three control groups with a total of 23
mice. There were seven DNFB dose groups
with an average of7 mice per group (range,
5-10 mice). The dose-response curve with
the four dose regimen was relatively steep,
with no observed tumors at a concentration
of 0.05%. A dose-squared (quadratic)
model gave the best fit to the data and took
the form 0.3 + 25 (dose) + 286 (dose)2.
The effect of age at the time of initial
dose and the resultant tumor response 8
weeks later is shown in Figure 4 (age range
of 16-32 weeks). There was a progressive
increase of tumor yield with increasing age
at a dose level of0.20/o-0.25% and no effect
ofage at a dose level of0.1O/o-0.125%.
DNFB produced a dose-dependent
inflammatory reaction in the dermis mani-
fested by an increase in thickness and cellu-
larity and associated with epidermal hyper-
plasia. The inflammatory response was pre-
dominantly mononudear except for an occa-
sional focal abscess in hair follicles. A thin
scab was frequently seen above the hyper-
plastic epidermis and, when stained with
Feulgen stain for DNA, appeared loaded
with fragments ofnudei. Figure 5 shows the
monotonic increase in inflammation accord-
ingto the dose ofDNFB in terms ofcellular-
ity and dermal thickness. These measure-
ments were made on skin obtained 2-3 days
after the fourth dose of DNFB. When the
two measures of inflammation were com-
bined as an index ofinflammation, the dose
response was fairly linear (Fig. 5). At a
DNFB dose of 0.05% where there was no
observable tumor response, there was a dis-
cernable inflammatory reaction.
Experiments were performed to evaluate
the effects of FA on the inflammatory and
tumorigenic responses to DNFB and TPA.
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Figure 4. Tumor response to dinitrofluorobenzene
(DNFB) at 8 weeks after initial exposure for the
indicated ages and dose ranges.
The results are shown in Figure 6. Various
dose levels of DNFB and FA were used.
DNFB was given in four applications. FA
was given with DNFB, about 30 min earlier,
orbydailyapplications withthetwice-weekly
applications of DNFB. The inflammation
index for the experiments are shown in
Figure 6A, and the tumor responses are
shown in Figure 6B. No tumors were seen
when FA was given alone. Concurrent FA
doses of 2.5 pg somewhat reduced the
inflammation from DNFB at a dose of0.2%
(Fig. 6, Experiment 2), but did not affect the
tumoryield. When the doses ofboth DNFB
and FAwere lowered to evaluate the possibil-
ity that FA might be more effective with
smaller and less toxic doses of both agents
(Fig. 6, Experiment 3), the inflammatory
response to 0.125% DNFB was not affected
byconcurrent FAdoses of0.5 pgbutwas sig-
nificantly reduced by FA at the I-pg dose
level; there were corresponding effects on the
tumor yield but not to a level ofstatistical
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Figure 5. The dinitrofluorobenzene (DNFB)
dose-response relationship for inflammation
based on dermal cellularity (the number of dermal
nuclei/4400 pm2), dermal thickness (the indicated
number divided by 100 is the thickness ofthe der-
mis in tenths of a millimeter), and the inflamma-
tion index (the product of the dermal thickness
and cellularity).
significance. When a 1-pg dose of FA was
given for3 consecutivedays before the first of
the four doses ofDNFB and, thereafter, FA
and DNFB at 0.1% were given concurrently,
there were no statistically significant differ-
ences in the tumor yields or the inflammato-
ry reactions. The tumor response to 0.2%
DNFB was lower in Experiment 2 than in
Experiment 4 because ofthe age effectshown
in Figure 4. The tumor response was smaller
when the experiment was begun at age 16
weeks (Fig. 6, Experiment 2) than at age 24
weeks (Fig. 6, Experiment 4) at the same
0.2% DNFB dose. The ages at the start of
Experiments 2 through 6 are 16, 30, 27, 24,
and 24 weeks, respectively. The lack of age
standardization was a function of the avail-
abilityoftheTGAC mice.
Combined controls
DNFB,0.2%x4
DNFB+FA, 2.5j±gx4
DNFB,0.125%x4
DNFB+FA, 0.5 jigx4
DNFB+FA, 1 ttgx4
DNFB,0.1%x4
DNFB+FA, 1 jig x4
DNFB,0.2%x4
DNFB+FA, 1.5gg daily
TPA, 2.5j±gx4
TPA+FA, 2.5ggx4
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Figure 6. The inflammation index and corresponding tumor yield, at 8 weeks after the initial exposure, for
the combined controls and five separate experiments involving exposure to dinitrofluorobenzene (DNFB)
alone orthe combined exposure to DNFB and fluocinolone acetonide (FA). DNFB was given twice a week
for 2weeks. In the case ofthe combined DNFB-FA exposures,the dose for DNFB is the same asthe expo-
sureto DNFB alone in thatexperiment. Error bars representstandard errors; asterisks indicate p<0.05.
"Experiment number.
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Figure 6, Experiment 5 shows that FA
at the 1.5-pg dose level, when given daily,
produced both an increase in the inflam-
matory reaction and a marked increase in
the tumor yield; this dose regimen was
ulcerogenic in contrast to the others. There
was no difference in the effects ofdaily or
twice-daily FA exposure on the response to
DNFB. Figure 6, Experiment 6 shows the
virtual elimination ofTPA-induced tumor
formation when FA was given concurrent-
ly; the inflammatory response to TPA was
depressed by FAbut not eliminated.
A separate experiment on the FVB
mouse, the parent strain of the TG.AC
mouse, was done to determine whether the
lack ofa substantial depressing effect ofFA
on the inflammatory response to DNFB at
dose levels of up to 2.5 pg per application
was due to an inadequate dose levels ofFA.
In this study, individual groups of mice
were given FA doses of0, 4.5, 9, and 18 pg
twice weekly for 2 weeks or concurrently
with DNFB concentrations of 0%,
0.125%, and 0.25%. The effects on the
inflammatory response in the dermis are
shown in Figure 7, expressed separately as
cellularity and thickness. When DNFB was
given without FA, there was a dose-depen-
dent increase in dermal inflammation, both
in terms ofcellularity and thickness. When
FA was given without DNFB, there was lit-
tle effect on dermal cellularitybut the thick-
ness ofthe dermis progressively diminished
with increasing dose. Thinning of the der-
mis and epidermis and atrophy of the hair
follicles reached extremes at the higher two
FA doses. When FA and DNFB were given
concurrently, there was a depression of
inflammation only in association with gen-
eralized skin atrophy and in spite of the
increasing ulceration caused by the FA.
The induction of contact sensitization
by DNFB and TPA and the modification
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Table 1. Contact sensitization from dorsal skin exposure measured as elicited ear swelling in relationship
tothe inflammatory and tumor responses induced in the dorsal skin
Inflammation index Tumor response
Dorsal skin dose Ear swellinga(pm) (dorsal skin) (papillomas/mouse)
DNFB-none 26 5 1.8± 0.1 0
DNFB 0.2% x4 157 ± 40*b 9.7 ± 0.3 22.8 ± 4.3
DNFB 0.2% x4 + FA 2.5 pg daily 70 ± 28 12.3 ± 0.6 40.3 ± 3.0
DNFB 0.1% x4 180±17* 5.5±0.4 4.3±1.3
DNFB0.1%x4+FA1 pgx4c 237±21 7.2±0.7 2.6±1.0
DNFB 0.05% x4 75 11* 5.6± 0.2 0
DNFB0.05%x4+FA2pgx4 117±57 4.1 ±0.3 0.3±0.3
TPA-none 30 ±6 1.8± 0.1 0
TPA0.003% x4 87 ± 28d 8.5± 2.1 12.0 ± 2.2
TPA003%x4+FA2.5pgdaily 30±6 1.8±0.1 0.3±0.2
aAverage incremental swelling(treated -nontreated) per eargiven as mean ± standard error.
bAsterisks refertotreatments that are statistically significantwith respectto controls; p<0.05.
CFAwas given for3 days priortothe four combined exposures.
dp= 0.1.
ofthis sensitization by FA, as measured by
the elicitation of ear swelling in TG.AC
mice, is shown in Table 1; experiments
shown in Figure 6 that did not have ear
measurements are omitted. The data across
experiments is not strictly comparable
because ofdifferences in DNFB concentra-
tions applied to one or two sides ofthe ear
(0.1-0.2%) and the elapsed time since
treatment of the dorsal skin; however, the
same technique was used within experi-
ments that evaluated the effect of FA on
the responses to DNFB and TPA. The irri-
tant effect on the ear swelling by DNFB or
TPA, i.e., in the absence of treatment of
the dorsal skin, was minor. Contact sensiti-
zation was induced by the full range of
DNFB dosage applied to the dorsal skin,
even at the 0.05% level, which did not
induced tumors although it did produce
dermal inflammation. The effect of FA on
the induction of contact sensitization by
DNFB was variable and there was a lack of
concordance between the modulation of
contact sensitization by FA and the corre-
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Figure 7. Dermal thickness and cellularity in response to dinitro
acetonide (FA) in the FVB mouse.
sponding effects on dermal inflammation
and tumor yields. Only TPA showed an
FA-induced concordant reduction in con-
tact sensitization, dermal inflammation,
and tumor formation. There was a com-
plete lack of correlation between the
amount ofear swelling induced by the elic-
iting doses of DNFB and the tumor yield
on individual mice (Fig. 8).
Discussion
This study shows that TG.AC mouse skin
responds to DNFB with tumor formation
and that the corticosteroid FA, applied
twice a week with DNFB, does not appre-
ciably block the inflammatory or tumor
response to DNFB as it does with TPA.
Both the inflammatory and tumorigenic
responses increased with daily exposure to
FA, in association with an increase in
DNFB-caused skin damage.
Corticosteroids are effective in blocking
the elicitation of contact sensitization in
the mouse skin (37). The failure of FA to
substantially reduce the inflammatory
response to DNFB in these experiments
suggests that, although DNFB is a contact
sensitizer, the inflammation at the dose lev-
els administered was duepredominantly to
cytotoxicity and not an immune-specific
response. Whether immunosuppression by
FA had any enhancing effect on tumor for-
mation because of impairment of immune
surveillance is not known; however, it
would not appear to be important because
the FA-induced reductions in inflamma-
tion that did occur were associated with a
decrease in tumor yield. The only instance
in which tumorigenesis increased was in
association with increased skin damage and
0 4.5 9.0 18.0 an increase in inflammation.
The exacerbation of DNFB-induced
skin damage by FA is probably due to the
fluorobenzene (DNFB) and fluocinolone ability ofcorticosteroids to inhibit cell pro-
liferation and consequently proliferative
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Figure 8. The association between tumor yield
and contact sensitization in the TG.AC mouse.
Each point represents, for a given mouse, its
tumor yield at 8 weeks after the first exposure to
dinitrofluorobenzene (DNFB) and the amount of
ear swelling at 24 hr after an eliciting dose of
DNFB was applied tothe ear.
repair (38); this effect might be the basis
for the observation of Woodworth et al.
(29) that FA enhanced the promoting
action off-propriolactone in mice initiated
by DMBA.
The cytotoxic induction of a tumor
response by DNFB may be analogous to
physicalwounding, which causes tumorpro-
motion in normal (39), aswell as inTGAC,
mouse skin J. Spalding, unpublished data).
Why physical or chemical wounding causes
tumor promotion is not known, but they
both involve cell damage and inflammation.
Measures that speed the repair ofsurgical
wounding reduce the yield oftumors in the
TG.AC mouse (J. Spalding, unpublished
data). This may be relevant to the lower
tumor response ofyounger mice at relatively
high DNFB doses (Fig. 4) because younger
animalstend tohealfaster.
DNFB is a tumor promoter for DMBA
in four strains ofmice other than TG.AC,
supporting the idea that theTG.AC mouse
behaves as if it were initiated (34). The
TGAC model is a curious reversal of the
usual initiation-promotion system because,
in its conventional form, the rare event is
initiation and the generalized effect is pro-
motion. With the TG.AC mouse, initia-
tion is the general event because all ofthe
cells have the transgene; promotion is the
uncommon event, which presumably
occurs in the stem cells of hair follicles
where the tumors arise (40).
The question is unanswered as to
whether cytotoxicity per se or the inflam-
mation induced by cytotoxicity is responsi-
ble for the tumorigenic effect of DNFB.
Inflammation, at the tissue level, has two
functions: the dean up ofcellular debris by
protease digestion and the stimulation of
proliferative repair by cytokines (41).
Protease digestion has its intracellular coun-
terpart in terms of removal of adducted
proteins (41). Cytotoxic inflammatory cells,
which function in cell-mediated immunity,
kill by injecting proteases into target cells
(41). Proteases are important in tumor pro-
motion because promotion is blocked by
protease inhibitors (42). Cytokine stimula-
tion in the injured skin was evidenced by
the hyperplastic epidermis in the high-dose
DNFB-treated skin and the heightened rate
oftumor growth at the margins ofhealing
ulcers. Perhaps the tumorigenic process in
theTG.AC mouse skin involves heightened
transgene expression in the occasional sur-
viving follicle stem cell that has been
injured by protein adducts and is being
stimulated by cytokines to proliferate while
underprotease attack. Interest in the role of
protein damage has historical aspects; itwas
an important concept in the pre-DNA era
ofcarcinogenesis theory (43).
The DNFB regimen in these experi-
ments involved relatively acute and high-
level exposures; perhaps this favored cyto-
toxicity as the dominant mode of inflam-
mation. Contact sensitizers, individually,
may have two dose responses: one for
immunogenic inflammation and the other
for cytotoxic inflammation. The relative
potencies ofcytotoxicityand immunogenic-
ity may differ among different contact sen-
sitizers, and the dose-response curves may
not be parallel. Perhaps prolonged low-dose
administration ofsome contact sensitizers,
induding DNFB, mightminimize cytotoxi-
city and result in predominantly immuno-
genic inflammation with a relatively long
latency period for tumor induction.
Contact sensitizers can be tumorigenic in
the TG.AC mouse with a longer latency
than for DNFB; for example, tripropylene
glycol diacrylate, which is a contact sensitiz-
er for both humans and mice, required
about 12 weeks of continuous exposure at
dose levels that did not induce epidermal
hyperplasia to induceskin tumors (44).
FA did not block the systemic aspects
of contact sensitization because this
occurred with all time and dose patterns of
DNFB administration. The lack of rele-
vance of the systemic manifestations of
contact sensitization to the skin tumor
response at the site of DNFB applications
was seen in the lack ofcorrelation of the
strength of systemic sensitization to the
tumoryield in individual mice (Fig. 8).
The dosage ofFA required to substan-
tially reduce the DNFB-induced inflamma-
tion caused considerable atrophy of the
skin and dissolution of the hair follicles;
under these circumstances, a suppression of
tumorigenesis by FA, even if it did occur,
could not be ascribed to reduced inflam-
mation because ofthe skin atrophy.
In summary, our initial hypothesis that
tumor promotion by DNFB might be due
to its immunogenically induced inflamma-
tion was not supported by the high-dose,
short-term experiments reported here.
Hence, it is notyet known whether contact
sensitizers can be tumor promoters on the
basis of their immunogenic properties.
However, the induction ofcytotoxicity and
its inflammatory consequences, presumably
from protein adduction by contact sensitiz-
ers, may in itselfplay a role in environmen-
tal carcinogenesis.
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